Table 1.
Abnormal results | |||
---|---|---|---|
Serum albumin | 5.4 | 3.5–5.0 g/l | Jun 2020 |
4.5 | 3.8–4.8 g/l | Aug 2020 | |
Antiphospholipid antibodies | |||
Anti-beta-2 glycoprotein-1 IgM | 36 | 0–32 GPI IgM | Aug 2020 |
47 | Dec 2020 | ||
59 | Mar 2021 | ||
Anti-phosphatidylethanolamine IgM | 56.5 | <12 U/ml | Aug 2020 |
22.6 | Dec 2020 | ||
57.4 | Mar 2021 | ||
Anti-prothrombin IgG | 27 | 0–20 G units | Aug 2020 |
5 | Dec 2020 | ||
NP | Mar 2021 | ||
Anti-phosphatidylserine IgG | 15 | 0–11 GPS IgG | Aug 2020 |
11 | Dec 2020 | ||
13 | Mar 2021 | ||
Mast cell mediators | |||
Serum prostaglandin D2 | 181 | 35–115 pg/ml | Aug 2020 |
Chromogranin A | 205.3 | 0–101.8 ng/ml | Aug 2020 |
255.1 | Dec 2020 | ||
282.3 | Mar 2021 |
NP: not performed. Normal test results included: transthoracic echocardiogram with bubble study, pulmonary function testing, chest CT scan, complete blood count, electrolytes, creatinine, liver function tests, random cortisol, thyroid function tests, glycosylated haemoglobin, creatine phosphokinase, aldolase, heavy metals (blood lead, arsenic, mercury), iron studies, erythrocyte sedimentation rate, C-reactive protein, urinalysis, HIV, chronic hepatitis panel, Lyme antibody panel, RPR, vitamins B1, B6, B12 and D, serum immunoglobulins and protein electrophoresis, antinuclear antibodies (ANA/ENA), complements C3, C4, rheumatoid factor/anti-CCP, novel Sjogren’s panel (except for a single transient slightly positive antibody), thyroid antibodies, coeliac antibodies, paraneoplastic antibody panel, anti-IgE receptor antibody, lupus anticoagulant, anti-cardiolipin IgG/M/A, anti-beta-2 glycoprotein-1 IgG/A, anti-phosphatidylethanolamine IgG/A, anti-phosphatidylserine IgM/IgA, anti-phosphatidylserine-prothrombin IgG/M, tryptase, plasma histamine and IgE food and environmental panels.